Larissa S. Carnevalli

Oncology R&D
Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

A linear ontogeny accounts for the development of naive, memory, and tumor-infiltrating regulatory T cells in mice.

A linear ontogeny accounts for the development of naive, memory, and tumor-infiltrating regulatory T cells in mice.

Journal: Science immunology

Published: June 20, 2025

A linear ontogeny accounts for the development of naive, memory and tumour-infiltrating regulatory T cells in mice.

A linear ontogeny accounts for the development of naive, memory and tumour-infiltrating regulatory T cells in mice.

Journal: bioRxiv : the preprint server for biology

Published: July 29, 2024

Immunotherapy that improves response to chemotherapy in high-grade serous ovarian cancer.

Immunotherapy that improves response to chemotherapy in high-grade serous ovarian cancer.

Journal: Nature communications

Published: April 11, 2024

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.

Journal: NPJ breast cancer

Published: September 19, 2023

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.

Journal: NPJ breast cancer

Published: August 18, 2023

The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.

The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.

Journal: Nature communications

Published: July 10, 2023

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.

Journal: Cancer research

Published: March 03, 2023

Longitudinal tracking of T cell lymphomas in mice using flow cytometry.

Longitudinal tracking of T cell lymphomas in mice using flow cytometry.

Journal: STAR protocols

Published: January 09, 2023

Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.

Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.

Journal: NPJ breast cancer

Published: October 19, 2022

Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer.

Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer.

Journal: Oncogene

Published: July 02, 2022

Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer.

Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer.

Journal: Journal for immunotherapy of cancer

Published: February 21, 2022

A preclinical model of peripheral T-cell lymphoma GATA3 reveals DNA damage response pathway vulnerability.

A preclinical model of peripheral T-cell lymphoma GATA3 reveals DNA damage response pathway vulnerability.

Journal: EMBO molecular medicine

Published: February 02, 2022

Showing 1-12 of 28

Last Updated: 09/26/2026